Access cutting-edge solid tumors treatment through this clinical trial at a research site in Scottsdale. Study-provided care at no cost to qualified participants.
Access solid tumors specialists in Scottsdale at no cost
This study follows strict safety protocols and ethical guidelines
All study-related solid tumors treatment provided free
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
Sponsor: Tango Therapeutics, Inc.
Check if you qualify for this solid tumors clinical trial in Scottsdale, AZ
If you're searching for solid tumors treatment options in Scottsdale, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Scottsdale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.